Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker completed the acquisition of Artelon.

Stryker Completes Acquisition of Artelon, Inc.

National Vision Hlds

Investors interested in stocks from the Medical - Products sector have probably already heard of National Vision (EYE) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

EYE or SYK: Which Is the Better Value Stock Right Now?

Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.

Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?

Cintas Corp

Deere & Company

Charles Schwab

U.S. stocks did amazingly well in the first half this year and the second half is unlikely to be any different, says Christopher Carey – portfolio manager at Carnegie Investment Counsel. Following are the top four undervalued stocks that he expects will be the hidden gems in the back half of 2024.

These 4 undervalued stocks could be hidden gems of H2 2024

Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter of fiscal year 2024, that ended June 30, 2024.

Stryker to announce financial results for its second quarter of fiscal year 2024

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

PORTAGE, Michigan and CHARLOTTE, North Carolina, USA, June 18, 2024 /PRNewswire/ -- Stryker is bringing its innovative products, platforms and robotic technologies to IRCAD North America (IRCAD NA), a subsidiary of Atrium Health, as part of a multi-year agreement supporting the creation of a cutting-edge experiential education center in Charlotte, North Carolina. IRCAD NA is set to become the cornerstone of the first research building at "The Pearl," a new innovation district currently under construction in the heart of Charlotte.

Stryker joins Atrium Health affiliate IRCAD North America to advance surgical training and education

Alphabet

Honeywell

iRobot

Intuitive Surgical

Mobileye Global Inc

Rockwell Automation

Automation stocks can be a tricky subject fundamentally speaking. With advances in artificial intelligence combined with enhanced connectivity – as in the Internet of Things or IoT – machines can end up taking over human jobs.

7 Automation Stocks to Propel Your Portfolio to Profits

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

LIFEPAK 35, a clinically advanced monitor/defibrillator, reduces caregiver burden and streamlines workflow.1 PORTAGE, Mich., USA, June 4, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of LIFEPAK 35 monitor/defibrillator, the latest product in the monitor/defibrillator space, offering advanced technology and built on an intuitive1, modern platform to help advance patient care.

Stryker releases LIFEPAK 35 monitor/defibrillator

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon.

Stryker Announces Definitive Agreement to Acquire Artelon, Inc., Offering a Range of Soft Tissue Fixation Solutions for Orthopaedic Surgeons

Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.

Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe

DexCom

Medtronic

In a recent deep-dive research report on the state of the MedTech (medical technology) sector, Oppenheimer highlighted the potential of artificial intelligence (AI) in the sector, noting its capacity to save an estimated $200 billion to $300 billion annually through enhanced workflow management. Inspired by these findings, this article explores the three best MedTech stocks to buy now, each poised to capitalize on AI-driven advancements.

The 3 Best MedTech Stocks to Buy Now: May 2024

Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.

Stryker (SYK) Issues Safety Notice for Its Total Knee System

AMSTERDAM, Netherlands--(BUSINESS WIRE)--The first surgeries utilizing Stryker's Gamma4 Hip Fracture Nailing System were completed in Europe.

First European Surgeries Completed Using Stryker's Gamma4 Hip Fracture Nailing System

Johnson & Johnson

While the biotechnology sector may receive most of the attention under the broad healthcare umbrella, investors ought to spare some love for medical technology stocks. The enterprises undergirding these securities offer tremendously positive potential for overall patient outcomes.

HealthTech Heroes: 3 Medical Technology Stocks to Buy Before They Boom

Symbotic Inc

Automation continues to be a key driving force of technological innovation in the 21st century. Older industrial sectors have relied on automation for driving efficiencies across the use of various equipment.

3 Robotics Stocks to Buy Now: May 2024

Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.

Stryker declares a $0.80 per share quarterly dividend

AMSTERDAM--(BUSINESS WIRE)--Stryker announced the completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology.

First Surgeries Using Stryker's Infinity With Adaptis and Everlast Successfully Completed in Europe

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

Start Time: 16:30 January 1, 0000 5:28 PM ET Stryker Corporation (NYSE:SYK ) Q1 2024 Earnings Conference Call April 30, 2024, 16:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - VP and CFO Jason Beach - VP, Finance and IR Conference Call Participants Robert Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Shagun Singh Chadha - RBC Capital Vijay Kumar - Evercore Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Sam Brodovsky - Truist Joshua Jennings - Cowen Andrew Ranieri - Morgan Stanley Operator Welcome to the First Quarter 2024 Stryker Earnings Call. My name is Christine, and I'm your operator for today's call.

Stryker Corporation (SYK) Q1 2024 Earnings Call Transcript

Stryker Corp lifted its full-year profit forecast on Tuesday, owing to resilient demand for the company's medical devices and implants.

Stryker lifts 2024 profit forecast on strong demand for medical devices, implants

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Stryker (SYK) Q1 Earnings

Stryker (SYK) came out with quarterly earnings of $2.50 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.14 per share a year ago.

News for Stryker Stock (SYK)